---
title: "China Resources Pharmaceutical files board, committee and disclosure-responsible management list"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292458151.md"
description: "China Resources Pharmaceutical has filed its board, committee, and disclosure-responsible management list. Bai Xiaosong was named chairman and executive director, with Cheng Jie and Liu Changan appointed as executive directors and president. The announcement details the composition of non-executive and independent non-executive directors, along with the chairs and members of key board committees including the executive, audit, corporate governance, and remuneration committees."
datetime: "2026-07-13T08:34:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292458151.md)
  - [en](https://longbridge.com/en/news/292458151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292458151.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical files board, committee and disclosure-responsible management list

-   China Resources Pharmaceutical named Bai Xiaosong chairman and executive director; Cheng Jie executive director and president; Liu Changan executive director. \* Non-executive directors: Guo Wei, Sun Yongqiang, Wang Yuhang; Zhang Jing, Jiao Ruifang. \* Independent non-executive directors: Chiu Mun Wai, Fu Tingmei, Zhang Kejian; Shi Luwen. \* Board committee chairs: Bai Xiaosong executive committee, nomination committee; Chiu Mun Wai audit committee; Fu Tingmei corporate governance; Shi Luwen remuneration. \* Committee members include Cheng Jie, Liu Changan on executive committee; Guo Wei, Jiao Ruifang on audit; Sun Yongqiang on remuneration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12242256), on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Hikers 'relied too much' on AI and had to be rescued. A ranger says it wasn't the first AI-related mishap he's seen.](https://longbridge.com/en/news/298103029.md)
- [09:21 ETAICost.ai Expands Its Independent AI Cost, Policy and Governance Decision-Intelligence Platform for the Agentic, Multi-Model Enterprise](https://longbridge.com/en/news/298044578.md)
- [07:31 ETCodeROI Launches the CodeROI AI Agent: R&D Tax Credits, Section 174, and Software Capitalization on Your AI Spend](https://longbridge.com/en/news/297778052.md)
- [Polyfair unit PCE winding-up petition hearing adjourned to Oct. 14; debt revised to HK$ 2.63 million](https://longbridge.com/en/news/298022665.md)
- [InSilico Medicine Chairman to Boost Personal Stake with HKD16 Million Share Purchase](https://longbridge.com/en/news/297969985.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**